Top stories

Who is so effective in covachield and covacin? Learn everything, including the testing and price of both vaccines

On Sunday, India’s Drug Controller General (DGCI) announced the approval of the emergency use of the double-coronary vaccine. Prime Minister Narendra Modi has described it as helpful in moving towards a ‘covid-free India’. It is now hoped that the vaccination process in India will begin soon. However, vaccination will be given on priority basis at this time. All vaccine preparations have been completed. All the states and union territories had previously run dry.

The two vaccines approved by the DGCI for emergency use today are covishield and covacin. Two vaccines have been tested in India. Let us give you the necessary information about these two vaccines.

Developers and creators

Covishield Oxford University Pharma has developed in collaboration with Major AstraZeneca. Participating in the examination of the Institute of India in Serim.

Kovacin is India’s first indigenous vaccine against corona. It was developed by India Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology.

How are vaccines developed?

A replica of the lack of a chimpanzee viral vector has been used in Covishield. It is based on a weaker version of the common cold virus (adenovirus), which infects chimpanzees. It contains the genetic material of the SARS-CoV-2 virus spike protein. Vaccinal spike proteins are made after vaccination, which induces the immune system to attack CARS-Cavi-2 when subsequently infected.

Kovacin is an inactive vaccine. Inactivated vaccine that is developed by inactivating (killing) living microorganisms as the cause of the disease. It destroys the ability to repeat the disease. But it has kept it at a stage where the immune system can still recognize it and build resistance. India Biotech reports that there are several inactive vaccines against hepatitis A, influenza, polio and rabies that provide “excellent protection”.

Testing and effectiveness

The Drug Controller said that the Serum Institute of India examined the data of more than 23,7454 foreign participants with 230.42 percent efficacy. It further said that 1,600 participants took part in the second and third phase tests conducted in India. Its results were comparable to the test in the first stage.

India conducted the first and second phase trials on Biotech 800 and participants. It was also tested on many other animals. The third trial is underway. A total of 22,500 participants took part. The vaccine has been shown to be effective and safe, the drug regulator said.

Vaccine costs

Frontline workers in India will get this vaccine for free. Union Health Minister Harsh Vardhan has already cleared it. So the cost will be clear later. Ginger Punawala, chief executive of the Seram Institute, had earlier said that the price of a cove shield could be around Rs 400. India Biotech vaccine can cost below Rs 100. However, nothing final can be said about the cost.


Show More

Related Articles

Leave a Reply

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker